Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to tackle obesity and diabetes together

NCT ID NCT06845202

Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 5 times

Summary

This early-stage study tests an experimental drug called ALN-4324 in two groups: healthy overweight volunteers and overweight patients with type 2 diabetes. The goal is to check the drug's safety and how well it controls blood sugar. Participants receive either the drug or a placebo, and researchers monitor side effects and blood sugar levels over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

105 people

The number who actually took part.

Started

Mar 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Part A: * Has a body mass index (BMI) of ≥27 kg/m\^2 and \<40 kg/m\^2 Part B: * Is an adult patient with a confirmed diagnosis of T2DM * Has a hemoglobin A1c (HbA1c) ≥7% to \<10.5% * Has a BMI of ≥25 kg/m\^2 and \<45 kg/m\^2 * Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) Exclusion Criteria: Part A: * Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection Part B: * Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i Note: other protocol defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese or overweight healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese or overweight healthy volunteers Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Clinical Trial Site

    Montclair, California, 91763, United States

  • Clinical Trial Site

    Washington D.C., District of Columbia, 20009, United States

  • Clinical Trial Site

    Miami, Florida, 33126, United States

  • Clinical Trial Site

    Marlton, New Jersey, 08053, United States

  • Clinical Trial Site

    Monroe, North Carolina, 28112, United States

  • Clinical Trial Site

    Dallas, Texas, 75230, United States

  • Clinical Trial Site

    Dallas, Texas, 75246, United States

  • Clinical Trial Site

    Buenos Aires, C1060, Argentina

  • Clinical Trial Site

    Buenos Aires, C1061AAE, Argentina

  • Clinical Trial Site

    Buenos Aires, C1061, Argentina

  • Clinical Trial Site

    San Miguel de Tucumán, T4000IHE, Argentina

  • Clinical Trial Site

    Concord, L4K 4M2, Canada

  • Clinical Trial Site

    Mount Royal, H3P 3P1, Canada

  • Clinical Trial Site

    Vancouver, V5Y 3W2, Canada

  • Clinical Trial Site

    Santiago, 7500710, Chile

  • Clinical Trial Site

    Santiago, 7770086, Chile

  • Clinical Trial Site

    Santiago, 8320000, Chile

  • Clinical Trial Site

    Essen, 45355, Germany

  • Clinical Trial Site

    Gdansk, 80-546, Poland

  • Clinical Trial Site

    Tarnów, 33-100, Poland

  • Clinical Trial Site

    Warsaw, 02-507, Poland

  • Clinical Trial Site

    Wroclaw, 51-162, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.